FMP

FMP

Enter

LPTX - Leap Therapeutics, I...

photo-url-https://images.financialmodelingprep.com/symbol/LPTX.png

Leap Therapeutics, Inc.

LPTX

NASDAQ

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

2.46 USD

-0.09 (-3.66%)

Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

-

1.5M

1.5M

-

-

-

-

-

-

-

Revenue %

-

-

-

-100

-

-25

-25

-25

-25

Operating Cash Flow

-26.9M

-25.96M

-35.16M

-49.04M

-43.75M

-

-

-

-

-

Operating Cash Flow %

100

-1.73k

-2.34k

100

100

20

20

20

20

Cap Ex

-100k

-

-

-

-

-

-

-

-

-

Cap Ex %

100

-

-

100

100

-

-

-

-

Free Cash Flow

-27M

-25.96M

-35.16M

-49.04M

-43.75M

-

-

-

-

-

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep